Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Conditions
Kidney Failure, Chronic, Renal Insufficiency
Interventions
Belatacept, ATG, Rituximab, Total Body Irradiation, Thymic Irradiation, Combined Bone Marrow/Kidney Transplantation
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Conditions
Sickle Cell Disease
Interventions
Hematopoietic Stem Cell Transplantation
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Leukemia, Lymphoma
Interventions
Filgrastim, Rituximab, Cyclophosphamide, Cytarabine, Methotrexate, Prednisone, Hydrocortisone, Vincristine, Leucovorin
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
30 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Conditions
Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
lenalidomide, melphalan, prednisone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Systemic Lupus Erythematosus
Interventions
Abatacept, Placebo, Prednisone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
12
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more
Conditions
Leukemia
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, idarubicin, mercaptopurine, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
2,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
32
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 24 more
Conditions
Multiple Myeloma
Interventions
recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 70 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
34
States / cities
Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more
Conditions
Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, T Cell, Leukemia, Lymphoblastic, Acute
Interventions
EZN-3042, Cytarabine, Doxorubicin, Prednisone, Vincristine, PEG-asparaginase, Methotrexate, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more
Conditions
Multiple Myeloma
Interventions
Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide, Cyclosporine, Doxorubicin hydrochloride, Etoposide, Fludarabine phosphate, Prednisone, Vincristine Sulfate, Methotrexate, GMCSF (granulocyte macrophage colony stimulating factor), GCSF (granulocyte colony stimulating factor)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Asthma
Interventions
budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone
Drug
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
10 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Lakewood, California
Conditions
Acute Lymphoblastic Leukemia
Interventions
Ruxolitinib, Dasatinib, Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions
abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more
Completed Phase 2 Interventional Results available

Rituximab and Belimumab for Lupus Nephritis

NCT02260934
Conditions
Lupus Nephritis
Interventions
Rituximab, Cyclophosphamide, Prednisone, Methylprednisolone, Diphenhydramine, Acetaminophen, Belimumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Standard Steroid Treatment, The Standard Steroid Treatment, Plasma Exchange and rituximab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
5
States / cities
Danville, Pennsylvania • Philladelphia, Pennsylvania • Pittsburgh, Pennsylvania + 2 more
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fontana, California + 14 more
Conditions
Vasectomy Reversal
Interventions
Prednisone
Drug
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orem, Utah
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
Interventions
Etoposide, Doxorubicin, Vincristine, Prednisone, Cyclophosphamide, Inotuzumab Ozogamicin
Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Conditions
High-risk Large B-cell Lymphoma (LBCL)
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Etoposide, Rituximab, Doxorubicin, Vincristine, Prednisone
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
Conditions
Ulcerative Colitis Acute
Interventions
Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids
Drug
Lead sponsor
Berinstein, Jeffrey
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Previously Untreated Peripheral T-cell Lymphoma
Interventions
CC-486 Administration, CHOP Administration
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Tampa, Florida • St Louis, Missouri • New York, New York